Loading
Kyntra Bio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Wettig Thane, was filed 17 Nov 2025.
Kyntra Bio, Inc.: what insiders have been doing
Kyntra Bio, Inc., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 20 October 2025 and 20 October 2026, 2 insiders published 8 filings.
No insider sold shares on the market over the period. Instead, the filings list 1 purchase totalling €7,919, made by 1 insider. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 1 chief executive among the declarants. The largest single trade was a purchase of €7,919 by Wettig Thane, published on 17 November 2025.
Across the 5,453 companies tracked on its exchange, the median is 22 filings; at 8 filings, this issuer sits below that mark. Since 2016, the database holds 10 purchases and 708 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 183.5 m USD of net income.
The clock since the last published purchase (17 November 2025) now reads 338 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4.
Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
1,257
Thresholds
n/a
Buy Volume
€1M
10 ops. · all time
Sell Volume
€158M
708 ops. · all time
Who traded when
BuySaleJames A. Schoeneck2 buys
Thane Wettig2 buys
Since the insiders bought
- -38.6%Entry US$8.60 · Close 19 Oct 2026 US$5.28
- +29.2%Entry US$5.61 · Close at T+365 US$7.25
- -76.2%Entry US$28.00 · Close at T+365 US$6.65
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Kyntra Bio, Inc. Buy (bullish), based on 4 analysts. Average price target: US$38.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$4.85
Analyst consensus
4 analystsBuy
US$35.00Target US$38.50(+694%)US$43.00
Income statement
RevenueUS$6.4M
Gross profitUS$5.9M91% margin
EBITDA-US$48.8M-758% margin
Net incomeUS$183.5M3968.6% margin
Valuation
PER (forward)-0.3x
Beta1.05
Balance sheet & cash
Market capUS$19.6M
Total debtUS$73.1M
Free Cash Flow-US$4.8M
Profitability & ownership
ROA-22.5%
% insiders2.0%
% institutions24.7%
Last declaration on 9 September 2026
Declarations1,257 total
22 shares@ US$8.550.0000% mcap19.8% of flowCommon StockSEC:0002040705-26-000007:0
209 shares@ US$8.550.0001% mcap48.5% of flowCommon StockSEC:0001815638-26-000011:0
52 shares@ US$6.7136.8% of flowCommon StockSEC:0002040705-26-000005:0
60 shares@ US$6.8443.3% of flowCommon StockSEC:0002040705-26-000003:0
277 shares@ US$6.8451.5% of flowCommon StockSEC:0001815638-26-000003:0
52 shares@ US$8.4224.0% of flowCommon StockSEC:0002040705-25-000002:0
259 shares@ US$8.420.3% of flowCommon StockSEC:0001815638-25-000005:0
1,000 shares@ US$9.181.3% of flowCommon StockSEC:0001815638-25-000004:0
Canonical exit: 11 Feb 2026 (T+90)
51 shares@ US$7.832522.3% of flowCommon StockSEC:0001415889-25-024014:0
246 shares@ US$7.83250.3% of flowCommon StockSEC:0001415889-25-024012:0
23,567 shares@ US$5.0755.7% of flowCommon StockSEC:0001415889-25-019067:0
Canonical exit: 28 Sept 2025 (T+90)
145,000 shares@ US$0.34947.8% of flowCommon StockSEC:0001415889-25-008872:0
Canonical exit: 22 Jun 2025 (T+90)
250,000 shares@ US$0.35244.3% of flowCommon StockSEC:0001415889-25-008823:0
Canonical exit: 18 Jun 2025 (T+90)
22,038 shares@ US$0.391.3% of flowCommon StockSEC:0001415889-25-007459:0
7,008 shares@ US$0.390.3% of flowCommon StockSEC:0001415889-25-007457:0
2,325 shares@ US$0.3953.7% of flowCommon StockSEC:0001415889-25-007455:0
2,363 shares@ US$0.34210.1% of flowCommon StockSEC:0001415889-24-028743:0
2,792 shares@ US$0.34210.1% of flowCommon StockSEC:0001415889-24-028742:0
1,446 shares@ US$0.34210.2% of flowCommon StockSEC:0001415889-24-028744:0
16,050 shares@ US$0.392.0% of flowCommon StockSEC:0001415889-24-023090:0
17,395 shares@ US$0.390.7% of flowCommon StockSEC:0001415889-24-023088:0
2,363 shares@ US$0.390.1% of flowCommon StockSEC:0001415889-24-023089:0
20,840 shares@ US$0.471.5% of flowCommon StockSEC:0001415889-24-020745:0
782 shares@ US$1.130.1% of flowCommon StockSEC:0001415889-24-018145:0
22,123 shares@ US$1.17100.0% of flowCommon StockSEC:0001415889-24-016677:0
Canonical exit: 10 Sept 2024 (T+90)
25 of 1257 declarations
About Kyntra Bio, Inc.
Kyntra Bio, Inc. is a biotechnology company focused on developing innovative treatments for chronic diseases. It is listed on the NASDAQ under the ticker KYNTRA.
